Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 393-397, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-64166
ABSTRACT
Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors' knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Proteínas Tirosina Quinasas
/
Carcinoma de Células Renales
/
Carcinoma de Células Escamosas
/
Carcinoma de Pulmón de Células no Pequeñas
/
Supervivencia sin Enfermedad
/
Quimioterapia
/
Corea (Geográfico)
/
Pulmón
/
Neoplasias Pulmonares
Límite:
Anciano
/
Humanos
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS